Merck & Co., Inc. (NYSE:MRK) Shares Bought by Parthenon LLC

Parthenon LLC increased its holdings in Merck & Co., Inc. (NYSE:MRKGet Rating) by 3.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 161,481 shares of the company’s stock after buying an additional 5,088 shares during the quarter. Merck & Co., Inc. comprises approximately 1.9% of Parthenon LLC’s investment portfolio, making the stock its 15th largest holding. Parthenon LLC’s holdings in Merck & Co., Inc. were worth $13,250,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Bridgeworth LLC acquired a new position in Merck & Co., Inc. in the 1st quarter worth approximately $207,000. Brown Advisory Inc. grew its stake in shares of Merck & Co., Inc. by 3.5% during the 1st quarter. Brown Advisory Inc. now owns 3,238,205 shares of the company’s stock worth $257,413,000 after purchasing an additional 109,772 shares during the period. Pine Haven Investment Counsel Inc grew its stake in shares of Merck & Co., Inc. by 3.3% during the 1st quarter. Pine Haven Investment Counsel Inc now owns 13,449 shares of the company’s stock worth $1,103,000 after purchasing an additional 425 shares during the period. Intercontinental Wealth Advisors LLC grew its stake in shares of Merck & Co., Inc. by 2.5% during the 1st quarter. Intercontinental Wealth Advisors LLC now owns 6,841 shares of the company’s stock worth $561,000 after purchasing an additional 166 shares during the period. Finally, Checchi Capital Advisers LLC grew its stake in shares of Merck & Co., Inc. by 5.4% during the 1st quarter. Checchi Capital Advisers LLC now owns 27,293 shares of the company’s stock worth $2,239,000 after purchasing an additional 1,407 shares during the period. Institutional investors and hedge funds own 72.88% of the company’s stock.

Merck & Co., Inc. Price Performance

MRK traded up $0.25 on Friday, hitting $87.07. 331,272 shares of the company’s stock were exchanged, compared to its average volume of 8,495,317. The firm has a 50-day moving average price of $90.38 and a 200-day moving average price of $85.34. The company has a current ratio of 1.40, a quick ratio of 1.14 and a debt-to-equity ratio of 0.75. The stock has a market cap of $220.18 billion, a price-to-earnings ratio of 13.30, a P/E/G ratio of 1.18 and a beta of 0.32. Merck & Co., Inc. has a fifty-two week low of $70.89 and a fifty-two week high of $95.72.

Merck & Co., Inc. (NYSE:MRKGet Rating) last announced its quarterly earnings results on Thursday, July 28th. The company reported $1.87 earnings per share for the quarter, beating the consensus estimate of $1.69 by $0.18. The firm had revenue of $14.59 billion for the quarter, compared to analysts’ expectations of $13.85 billion. Merck & Co., Inc. had a net margin of 29.00% and a return on equity of 50.02%. The company’s revenue was up 28.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.31 EPS. As a group, equities analysts anticipate that Merck & Co., Inc. will post 7.31 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 7th. Stockholders of record on Thursday, September 15th will be given a dividend of $0.69 per share. The ex-dividend date is Wednesday, September 14th. This represents a $2.76 annualized dividend and a dividend yield of 3.17%. Merck & Co., Inc.’s payout ratio is 42.27%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on MRK shares. SVB Leerink reaffirmed an “outperform” rating and set a $102.00 price objective on shares of Merck & Co., Inc. in a research note on Monday, June 6th. Barclays raised their price objective on shares of Merck & Co., Inc. from $94.00 to $97.00 and gave the stock an “overweight” rating in a research note on Tuesday, April 12th. Cowen increased their target price on Merck & Co., Inc. from $95.00 to $102.00 and gave the company a “market perform” rating in a research report on Monday, June 27th. Cowen lifted their price target on shares of Merck & Co., Inc. from $95.00 to $102.00 and gave the company a “market perform” rating in a research note on Monday, June 27th. Finally, Daiwa Capital Markets raised shares of Merck & Co., Inc. from a “neutral” rating to a “buy” rating and lifted their price target for the company from $89.00 to $102.00 in a research note on Wednesday, July 6th. Eight analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $97.44.

Merck & Co., Inc. Company Profile

(Get Rating)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

Featured Stories

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKGet Rating).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.